Srikripa Devarakonda
Stock Analyst at Truist Securities
(2.88)
# 2,769
Out of 5,044 analysts
72
Total ratings
43.28%
Success rate
0.21%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Maintains: Buy | $76 → $88 | $77.22 | +13.96% | 3 | Oct 28, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $54 → $44 | $29.31 | +50.12% | 5 | Oct 20, 2025 | |
| VTRS Viatris | Initiates: Buy | $15 | $10.41 | +44.09% | 1 | Oct 15, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | $50 | $19.60 | +155.10% | 1 | Oct 15, 2025 | |
| MDGL Madrigal Pharmaceuticals | Initiates: Buy | $580 | $423.24 | +37.04% | 1 | Oct 15, 2025 | |
| TERN Terns Pharmaceuticals | Initiates: Buy | $20 | $8.30 | +140.96% | 1 | Oct 15, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $53 → $68 | $61.00 | +11.48% | 4 | Sep 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $940 → $812 | $657.30 | +23.54% | 8 | Aug 11, 2025 | |
| INCY Incyte | Maintains: Hold | $73 → $79 | $90.43 | -12.63% | 11 | Jul 30, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $21 → $11 | $9.55 | +15.18% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $199 | $149.07 | +33.49% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $15.38 | +62.55% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,029 → $1,038 | $821.27 | +26.39% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $211 → $217 | $226.70 | -4.28% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $24.41 | +31.09% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $16.25 | +207.69% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.40 | +3,757.14% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $8.75 | +71.43% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $11.63 | +209.68% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $62.26 | +12.43% | 4 | May 29, 2024 |
Protagonist Therapeutics
Oct 28, 2025
Maintains: Buy
Price Target: $76 → $88
Current: $77.22
Upside: +13.96%
Scholar Rock Holding
Oct 20, 2025
Maintains: Buy
Price Target: $54 → $44
Current: $29.31
Upside: +50.12%
Viatris
Oct 15, 2025
Initiates: Buy
Price Target: $15
Current: $10.41
Upside: +44.09%
MBX Biosciences
Oct 15, 2025
Initiates: Buy
Price Target: $50
Current: $19.60
Upside: +155.10%
Madrigal Pharmaceuticals
Oct 15, 2025
Initiates: Buy
Price Target: $580
Current: $423.24
Upside: +37.04%
Terns Pharmaceuticals
Oct 15, 2025
Initiates: Buy
Price Target: $20
Current: $8.30
Upside: +140.96%
Kymera Therapeutics
Sep 30, 2025
Maintains: Buy
Price Target: $53 → $68
Current: $61.00
Upside: +11.48%
Regeneron Pharmaceuticals
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $657.30
Upside: +23.54%
Incyte
Jul 30, 2025
Maintains: Hold
Price Target: $73 → $79
Current: $90.43
Upside: -12.63%
Arvinas
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $9.55
Upside: +15.18%
Apr 29, 2025
Maintains: Buy
Price Target: $210 → $199
Current: $149.07
Upside: +33.49%
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $15.38
Upside: +62.55%
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $821.27
Upside: +26.39%
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $226.70
Upside: -4.28%
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $24.41
Upside: +31.09%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $16.25
Upside: +207.69%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.40
Upside: +3,757.14%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $8.75
Upside: +71.43%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $11.63
Upside: +209.68%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $62.26
Upside: +12.43%